

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No. *ANG/23-24/BSE-150*

Date *01-02-2024*

To

Department of Corporate Services
BSE Limited
P.J. Towers, Dalal Street
Mumbai - 40001.

Ref.: Scrip Code – 540694

Sub: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations')

Dear Sir/Madam,

In reference to our earlier letter dated 31.01.2024, ANG/23-24/BSE-149, please find herewith enclosed the additional details under SEBI Circular no. CIR/CFD/CMD/4/2015 dated September 09, 2015 for amendment in the Asset Purchase agreement with Ind-Swift Ltd (14.08.2021) along with the Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015.

You are requested to kindly take the same on record.

For **ANG Lifesciences India Limited**




Renu
Kaur

Digitally signed by Renu Kaur
DN: cn=Renu Kaur, o=ANG Lifesciences India Limited,
ou=ANG Lifesciences India Limited, email=Renu.Kaur@anglifesciences.com,
c=IN

Renu Kaur
Company Secretary

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No. ANG/23-24/BSE-149

Date 31 Jan. 2024

To

Department of Corporate Services
BSE Limited
P.J. Towers, Dalal Street
Mumbai - 400001.

Ref.: Scrip Code – 540694

Sub: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations')

Dear Sir/Madam,

In reference to our disclosure dated 14.08.2021 about the Assets Purchase Agreement with Ind-swift Ltd wherein the Company had agreed to acquire two formulation units of Ind-Swift Ltd (Unit III & IV) located at Village Malku Majra Tehsil Nalagarh Baddi (H.P.) for a consideration of Rs. 60 Cr. (Rupees Sixty Crores) payable by internal accrual & bank funding on deferred payment basis up to 30-Jun-2024.

With respect to the above, we inform you that ANG Lifesciences and Ind Swift Ltd entered into an agreement to amend the previous Assets Purchase Agreement (14.08.2021).

In pursuant to amended agreement, the Board of ANG has decided to acquire only Unit III of Ind-Swift Ltd for a consideration of Rs. 43.00 Crs. (Rupees Forty-Three Crores) which is already paid to Ind-Swift Ltd. Further the Registration and other formalities would be done in due course of time and shall be intimate you accordingly.

The reason for not acquiring the Unit IV of Ind- swift Ltd is that the Company wants to sustain its liquidity without raising any debt. However the Unit IV of Ind- swift Ltd was unused since Oct-2022.

We request you to kindly take the above on record.

Thanking You
Yours' faithfully

For ANG Lifesciences India Limited



Renu Kaur
Company Secretary



Renu
Kaur

Digitally signed by Renu Kaur
DN: cn=Renu Kaur, o=ANG Lifesciences India Limited, email=renukaur@anglifesciences.com, c=IN
Date: 2024.01.31 12:21:11 +05'30'

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date.....

The details as required pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015 are as under:


Sn	Particulars	Details
1	Name(s) of the parties with whom the agreement is entered	Ind-Swift Ltd
2	Purpose of entering into the agreement	Amendment in the previous Assets Purchase agreement entered with Ind-Swift Limited on 14.08.2021, wherein the company (ANG) has agreed to acquire two formulations units, namely unit no. III & IV of Ind-Swift Ltd. located at Village Malku Majra, Tehsil —Nalagarh, Baddi, (H.P.) for a consideration of Rs. 60.00 Cr. (Rupees Sixty Crores Only). The Board has now approved an amendment in the aforesaid agreement and decided to acquire only Unit no. III of Ind-Swift Ltd, for a sum of Rs. 43.00 Cr. (Rupees Forty-Three Crores Only).
3	Shareholding, if any, in entity with whom agreement is executed	None
4	Significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure	The changes in the Agreement is only with respect to: • Acquire only Unit III of Ind-Swift Ltd for a consideration of Rs. 43.00 Crs. (Rupees Forty-Three Crores).
5	Whether the said parties are related to promoter/promoter group companies in any manner. If yes, nature of relationship	None
6	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arms length"	None
7	In case of issuance of shares to the parties, details of issue price, class of shares issued	No issuance of shares
8	Any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc.	Not applicable
9	In case of termination—or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s): a) name of parties to the agreement; b) nature of the agreement; c) date of execution of the agreement;	a) Name of parties to the agreement: Please refer point no. 1 b) Nature of the Agreement: Amendment in the Assets Purchase agreement dated 14.08.2021 c) Date of Execution of the agreement: 31.01.2024

Renu
Kaur

Digitally signed by Renu Kaur
DN: cn=Renu Kaur, o=ANG Lifesciences India Limited, email=Renu.Kaur@anglifesciences.com, c=IN
Date: 2024.01.31 10:24:57 +05'30'



CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date.....

<p>d) details of amendment and impact thereof or reasons of termination and impact thereof.</p>	<p>Details of amendment and impact thereof or reasons of termination and impact thereof: In pursuant to amended agreement, the Company (ANG) has decided to acquire only Unit III of Ind-Swift Ltd for a consideration of Rs. 43.00 Crs. (Rupees Forty-Three Crores) which is already paid to Ind-Swift Ltd.</p> <p>The execution of the Amendment Agreement will not result in any effective change in management and control of the Company.</p>
---	---



Renu
Kaur

